ReviewCancer management and research2026
The Evolving Role of Local Radiotherapy in the Management of Oligometastatic Non-Small Cell Lung Cancer.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligometastasis represents an intermediate stage between locally advanced disease and widespread metastasis, typically referring to stage IV disease with a limited number of metastatic lesions (generally no more than five) and controlled primary disease. Traditionally, advanced non-small cell lung cancer (NSCLC) has been considered incurable, relying primarily on systemic therapies. However, the "oligometastasis hypothesis" proposes that radical local radiotherapy targeting metastatic lesions in such patients may eliminate all tumor burden, potentially achieving long-term survival or even cure. This review aims to elucidate the pivotal role of localized radiotherapy in oligometastatic NSCLC by examining its clinical landscape and therapeutic challenges. Furthermore, This review uniquely integrates biological stratification, technological innovation, and systemic treatment synergy to provide a comprehensive framework for patient selection and clinical decision-making in oligometastatic NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.